Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Advanced prostate cancer (PCa) often develops resistance to androgen deprivation therapy (ADT), progressing to castration-resistant prostate cancer (CRPC).
• The molecular drivers underlying CRPC development remain largely undefined, representing a significant clinical challenge.
• Nuclear receptor coactivator 2 (NCoA2), also known as SRC-2, is frequently amplified or overexpressed in metastatic PCa.

Purpose of the Study:

• To investigate the role of NCoA2 in the development and progression of prostate cancer, particularly CRPC.
• To elucidate the molecular mechanisms by which NCoA2 influences PCa malignancy and metastasis.
• To assess the therapeutic potential of targeting NCoA2 for prostate cancer treatment.

Main Methods:

• Utilized a murine model of prostate cancer with NCoA2 overexpression and Pten deletion.
• Depleted NCoA2 in PTEN-deficient mice to assess its necessity for CRPC development.
• Analyzed NCoA2 expression and signaling pathways (PI3K/AKT, MAPK) in human prostate cancer cells and patient samples.

Main Results:

• Overexpression of NCoA2 in prostate epithelium promoted neoplasia and metastasis in a murine model.
• NCoA2 depletion prevented CRPC development in PTEN-deficient mice.
• NCoA2 overexpression led to hyperactivation of PI3K/AKT and MAPK signaling, correlating with PCa progression and recurrence in patients.

Conclusions:

• Androgen deprivation induces NCoA2 expression, which mediates PI3K signaling activation, promoting PCa metastasis and CRPC development.
• NCoA2 acts as a key mediator in the transition from androgen-sensitive to castration-resistant prostate cancer.
• Targeting NCoA2 represents a promising therapeutic strategy for managing advanced and metastatic prostate cancer.